Full Breakdown
Oxford Launches First Human Trial of Bundibugyo Ebola Vaccine
7/13/2026, 9:34:49 PM
Core Event: Phase 1 Trial Begins in Oxford
On 13 July 2026 the University of Oxford started recruiting 50 healthy adults aged 18-55 for the BD-Ebov (ChAdOx1 BDBV) trial in Oxford, England. The study will assess safety and immune response; vaccinations are slated to begin within weeks after regulatory clearance.
Background & Context
The Bundibugyo ebolavirus is driving an outbreak in the Democratic Republic of Congo and Uganda that has caused 625 deaths among 1,792 laboratory-confirmed cases, making it the third-largest Ebola outbreak on record. The World Health Organization declared a public-health emergency on 17 May 2026 and, in May, recommended that the ChAdOx1 BDBV candidate and the single-dose rVSV Bundibugyo vaccine (developed by the International AIDS Vaccine Initiative) be prioritised for clinical evaluation.
Key Figures & Partnerships
- Oxford Vaccine Group & Pandemic Sciences Institute – developers of the ChAdOx1 BDBV vaccine.
- Professor Teresa Lambe – lead scientific investigator at the Jenner Institute.
- Dr. Katrina Pollock – spokesperson for the UK regulator (MHRA).
- Dr. Nicole Lurie – executive director of the Coalition for Epidemic Preparedness Innovations (CEPI).
- Serum Institute of India – manufactured ~620,000 doses, supplying 4,000 investigational doses for the Phase 1 study.
- CEPI – provided an initial US$8.6 million investment.
- Future African trials will involve the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine Uganda Research Unit.
Data & Statistics
- Trial size: 50 volunteers, ages 18-55.
- Manufacturing: 620,000 doses stockpiled; 4,000 allocated for the early-stage study.
- Case fatality rate: estimated 30-40 % for the Bundibugyo strain.
- Outbreak figures: 625 fatalities, 1,792 confirmed infections.
Why It Matters
This is the first human evaluation of a vaccine targeting the Bundibugyo strain, which lacks any approved prophylaxis. The candidate uses the ChAdOx1 viral-vector platform proven in the Oxford/AstraZeneca COVID-19 vaccine, enabling an eight-week development timeline after the WHO emergency declaration. A single-dose, thermostable formulation could overcome logistical hurdles in conflict-affected regions where traditional ring-vaccination is impractical, potentially curbing transmission across highly mobile populations.
Official Statements & Responses
- The UK Medicines and Healthcare products Regulatory Agency granted trial permission, citing the established safety record of the ChAdOx1 vector.
- WHO’s May 2026 recommendation highlighted the urgent need for strain-specific tools.
- CEPI announced an initial US$8.6 million investment and pledged continued collaboration if early results are encouraging.
- Oxford University stressed its goal to ensure rapid, affordable vaccine supplies for the affected countries.
Verbatim Quotes
- “We're doing phase one (early stage) trials of new vaccines all of the time, precisely to be ready for exactly this kind of outbreak” — Dr. Katrina Pollock, UK regulator spokesperson
- “The deadly Bundibugyo epidemic is already the third-largest Ebola outbreak on record, and infection numbers are continuing to rise.” — Dr. Nicole Lurie, CEPI executive director
- “The University of Oxford's work to progress their Bundibugyo vaccine candidate ready to enter Phase I trials in a matter of weeks is a pivotal milestone in the response effort.” — Dr. Nicole Lurie, CEPI
- “Speaking from the Oxford research facility, Lambe noted that the ongoing outbreak continues to devastate affected communities, underlining an urgent mandate for effective countermeasures.” — Professor Teresa Lambe, Lead Investigator, Jenner Institute
What's Next
If the Phase 1 data demonstrate acceptable safety and immunogenicity, CEPI will work with Oxford and the Serum Institute to launch Phase II/III trials, including sites in Uganda pending regulatory approval. Results from the 12-month follow-up of the UK cohort will inform decisions on emergency-use authorization and broader deployment.